表紙
市場調査レポート

重症急性呼吸器症候群 (SARS) コロナウイルス感染症:パイプライン分析

Severe Acute Respiratory Syndrome (SARS) Coronavirus Infection - Pipeline Review, H1 2016

発行 Global Markets Direct 商品コード 255961
出版日 ページ情報 英文 59 Pages
即納可能
価格
本日の銀行送金レート: 1USD=101.50円で換算しております。
Back to Top
重症急性呼吸器症候群 (SARS) コロナウイルス感染症:パイプライン分析 Severe Acute Respiratory Syndrome (SARS) Coronavirus Infection - Pipeline Review, H1 2016
出版日: 2016年03月09日 ページ情報: 英文 59 Pages
概要

重症急性呼吸器症候群 (SARS) は、コロナウイルス科のウイルスによって引き起こされる、重篤で、生命に関わる恐れのあるウイルス感染症です。咳、悪寒や震え、頭痛、筋肉痛、下痢、めまい、悪心や嘔吐などの症状が見られます。危険因子として、免疫系の遺伝子変異、感染者との緊密な接触が挙げられます。

当レポートでは、重症急性呼吸器症候群 (SARS) コロナウイルス感染症に対する治療薬の開発状況について調査分析し、パイプライン製品の概要、治験の段階別の製品の概要、主要企業プロファイル、薬剤プロファイル、パイプライン製品の最新動向、最新ニュースとプレスリリースなどについて、体系的な情報を提供しています。

目次

イントロダクション

重症急性呼吸器症候群 (SARS) コロナウイルス感染症の概要

治療薬の開発

  • パイプライン製品:概要
  • パイプライン製品:比較分析

開発中の治療薬:企業別

調査中の治療薬:大学/研究機関別

パイプライン製品の概要

  • 治験段階の製品
  • 初期段階の製品

開発中の製品:企業別

調査中の製品:大学/研究機関別

治療薬の開発に従事している企業

  • CEL-SCI Corporation
  • GeneCure LLC
  • Humabs BioMed SA
  • Inovio Pharmaceuticals, Inc.
  • Nanotherapeutics, Inc.
  • Novavax, Inc.
  • Phelix Therapeutics, LLC
  • Protein Sciences Corporation

治療薬の評価

  • 単独療法の場合
  • 併用療法の場合
  • 標的別
  • 作用機序別
  • 投与経路別
  • 分子タイプ別

薬剤プロファイル

  • CEL-1000
  • D-3252
  • 感染症向け Cathepsin L阻害薬
  • FDX-000
  • INO-4500
  • LCA-60
  • 中東呼吸器症候群ワクチン + 重症急性呼吸器症候群ワクチン
  • ML-188
  • SARSウィルス感染症向けモノクローナル抗体
  • RBD-219N1
  • SARS (ウイルス様粒子) ワクチン
  • SARS ワクチン
  • SARSワクチン
  • SARS・エボラウィルス感染症向け Cathepsin L 阻害小分子
  • SSYA-10001
  • thiocarbazate

パイプライン製品の最新動向

休止状態のプロジェクト

開発が中止された製品

製品開発のマイルストーン

  • 最新ニュースとプレスリリース

付録

図表

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: GMDHC7731IDB

Summary

Global Markets Direct's, 'Severe Acute Respiratory Syndrome (SARS) Coronavirus Infection - Pipeline Review, H1 2016', provides an overview of the Severe Acute Respiratory Syndrome (SARS) Coronavirus Infection pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Severe Acute Respiratory Syndrome (SARS) Coronavirus Infection, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Severe Acute Respiratory Syndrome (SARS) Coronavirus Infection and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Severe Acute Respiratory Syndrome (SARS) Coronavirus Infection
  • The report reviews pipeline therapeutics for Severe Acute Respiratory Syndrome (SARS) Coronavirus Infection by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved Severe Acute Respiratory Syndrome (SARS) Coronavirus Infection therapeutics and enlists all their major and minor projects
  • The report assesses Severe Acute Respiratory Syndrome (SARS) Coronavirus Infection therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news related to pipeline therapeutics for Severe Acute Respiratory Syndrome (SARS) Coronavirus Infection

Reasons to buy

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of therapeutics under development for Severe Acute Respiratory Syndrome (SARS) Coronavirus Infection
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Severe Acute Respiratory Syndrome (SARS) Coronavirus Infection pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Severe Acute Respiratory Syndrome (SARS) Coronavirus Infection Overview
  • Therapeutics Development
    • Pipeline Products for Severe Acute Respiratory Syndrome (SARS) Coronavirus Infection - Overview
    • Pipeline Products for Severe Acute Respiratory Syndrome (SARS) Coronavirus Infection - Comparative Analysis
  • Severe Acute Respiratory Syndrome (SARS) Coronavirus Infection - Therapeutics under Development by Companies
  • Severe Acute Respiratory Syndrome (SARS) Coronavirus Infection - Therapeutics under Investigation by Universities/Institutes
  • Severe Acute Respiratory Syndrome (SARS) Coronavirus Infection - Pipeline Products Glance
    • Clinical Stage Products
    • Early Stage Products
  • Severe Acute Respiratory Syndrome (SARS) Coronavirus Infection - Products under Development by Companies
  • Severe Acute Respiratory Syndrome (SARS) Coronavirus Infection - Products under Investigation by Universities/Institutes
  • Severe Acute Respiratory Syndrome (SARS) Coronavirus Infection - Companies Involved in Therapeutics Development
    • CEL-SCI Corporation
    • GeneCure LLC
    • Humabs BioMed SA
    • Inovio Pharmaceuticals, Inc.
    • Nanotherapeutics, Inc.
    • Novavax, Inc.
    • Phelix Therapeutics, LLC
    • Protein Sciences Corporation
  • Severe Acute Respiratory Syndrome (SARS) Coronavirus Infection - Therapeutics Assessment
    • Assessment by Monotherapy Products
    • Assessment by Combination Products
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Drug Profiles
    • CEL-1000 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • D-3252 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Drugs to Inhibit Cathepsin L for Infectious Diseases - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • FDX-000 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • INO-4500 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • LCA-60 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • middle east respiratory syndrome vaccine + severe acute respiratory syndrome vaccine - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • ML-188 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Monoclonal Antibody for SARS Virus Infections - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • RBD-219N1 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • SARS (virus like particle) vaccine - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • SARS vaccine - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • SARS vaccine - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • severe acute respiratory syndrome vaccine - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Small Molecule to Inhibit Cathepsin L for SARS and Ebola Viral Infections - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • SSYA-10001 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • thiocarbazate - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
  • Severe Acute Respiratory Syndrome (SARS) Coronavirus Infection - Recent Pipeline Updates
  • Severe Acute Respiratory Syndrome (SARS) Coronavirus Infection - Dormant Projects
  • Severe Acute Respiratory Syndrome (SARS) Coronavirus Infection - Discontinued Products
  • Severe Acute Respiratory Syndrome (SARS) Coronavirus Infection - Product Development Milestones
    • Featured News & Press Releases
      • Oct 19, 2015: Inovio and Partner Advance MERS Vaccine
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for Severe Acute Respiratory Syndrome (SARS) Coronavirus Infection, H1 2016
  • Number of Products under Development for Severe Acute Respiratory Syndrome (SARS) Coronavirus Infection - Comparative Analysis, H1 2016
  • Number of Products under Development by Companies, H1 2016
  • Number of Products under Investigation by Universities/Institutes, H1 2016
  • Comparative Analysis by Clinical Stage Development, H1 2016
  • Comparative Analysis by Early Stage Development, H1 2016
  • Products under Development by Companies, H1 2016
  • Products under Investigation by Universities/Institutes, H1 2016
  • Severe Acute Respiratory Syndrome (SARS) Coronavirus Infection - Pipeline by CEL-SCI Corporation, H1 2016
  • Severe Acute Respiratory Syndrome (SARS) Coronavirus Infection - Pipeline by GeneCure LLC, H1 2016
  • Severe Acute Respiratory Syndrome (SARS) Coronavirus Infection - Pipeline by Humabs BioMed SA, H1 2016
  • Severe Acute Respiratory Syndrome (SARS) Coronavirus Infection - Pipeline by Inovio Pharmaceuticals, Inc., H1 2016
  • Severe Acute Respiratory Syndrome (SARS) Coronavirus Infection - Pipeline by Nanotherapeutics, Inc., H1 2016
  • Severe Acute Respiratory Syndrome (SARS) Coronavirus Infection - Pipeline by Novavax, Inc., H1 2016
  • Severe Acute Respiratory Syndrome (SARS) Coronavirus Infection - Pipeline by Phelix Therapeutics, LLC, H1 2016
  • Severe Acute Respiratory Syndrome (SARS) Coronavirus Infection - Pipeline by Protein Sciences Corporation, H1 2016
  • Assessment by Monotherapy Products, H1 2016
  • Assessment by Combination Products, H1 2016
  • Number of Products by Stage and Target, H1 2016
  • Number of Products by Stage and Mechanism of Action, H1 2016
  • Number of Products by Stage and Route of Administration, H1 2016
  • Number of Products by Stage and Molecule Type, H1 2016
  • Severe Acute Respiratory Syndrome (SARS) Coronavirus Infection Therapeutics - Recent Pipeline Updates, H1 2016
  • Severe Acute Respiratory Syndrome (SARS) Coronavirus Infection - Dormant Projects, H1 2016
  • Severe Acute Respiratory Syndrome (SARS) Coronavirus Infection - Dormant Projects (Contd..1), H1 2016
  • Severe Acute Respiratory Syndrome (SARS) Coronavirus Infection - Discontinued Products, H1 2016

List of Figures

  • Number of Products under Development for Severe Acute Respiratory Syndrome (SARS) Coronavirus Infection, H1 2016
  • Number of Products under Development for Severe Acute Respiratory Syndrome (SARS) Coronavirus Infection - Comparative Analysis, H1 2016
  • Number of Products under Development by Companies, H1 2016
  • Number of Products under Investigation by Universities/Institutes, H1 2016
  • Comparative Analysis by Early Stage Products, H1 2016
  • Assessment by Monotherapy Products, H1 2016
  • Number of Products by Targets, H1 2016
  • Number of Products by Stage and Targets, H1 2016
  • Number of Products by Mechanism of Actions, H1 2016
  • Number of Products by Stage and Mechanism of Actions, H1 2016
  • Number of Products by Routes of Administration, H1 2016
  • Number of Products by Stage and Routes of Administration, H1 2016
  • Number of Products by Top 10 Molecule Types, H1 2016
  • Number of Products by Stage and Top 10 Molecule Types, H1 2016
Back to Top